Pfizer begins testing use of pneumococcal vaccine along with COVID-19 booster shot

[May 24, 2021]  (Reuters) - Pfizer Inc said on Monday it has started immunizing the first patients in a new study looking at administering the company's 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 shot.

The study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech COVID-19 vaccine, and will have received their second dose of the vaccine at least six months prior to entering the co-administration study, the company said.

(This story has been refiled to correct spelling of pneumococcal in headline)

(Reporting by Vishwadha Chander in Bengaluru; Editing by Sriraj Kalluvila)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content